Acquiring drug candidate orismilast from Leo Pharma in summer of last year in a deal valued up to DKK 1.2bn (USD 186.4m) has turned out to be a good decision for Union Therapeutics.
Last month, the company entered into a strategic collaboration and license agreement about orismilast with the Chinese company Innovent Biologics, which could end up paying Union Therapeutics up to USD 267m for the exclusive rights to the research, development and commercialization of the drug in China, Hong Kong, Macau and Taiwan. It was also recently revealed that the US Food and Drug Administration has fast-tracked the former Leo Pharma eczema candidate, which is an oral treatment for atopic dermatitis, commonly known as eczema.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
New CCO at crisis-hit Lundbeck: "2022 will be a growth year for Lundbeck in all regions"
Jacob Tolstrup will be responsible for renewing sales growth at Lundbeck, having made his way through the ranks.
Coloplast upgrades growth expectations following acquisition
Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.
Demant's surgical division loses president of 13 years
Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.
Hearing aid market in US grew by 37 percent in 2021
Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.
Lundbeck's migraine drug approved in EU
Vyepti has become the first approved intravenous preventative migraine treatment in the region.
Compound Development Team Lead 
Project Lead, Muna Therapeutics, Copenhagen, Denmark 
Director Medical Science 
Clinical Research Associate 
QA Specialist 
KLIFO is looking for a Director, Business Support for our Glostrup office 
Medical Director, Translational Medicine 
Chemists are wanted for ALK's internal Aircraft Corps 
Senior Scientist 
NORDIC Medical Sales Director 
Head of Biology Group Human Milk Oligosaccharides & Early Life Nutrition, DSM/Glycom 
Health Economist 
QA Manager GMP/GDP Compliance & Audits 
Senior Key Account Manager 
Commercial Excellence Lead 
Senior Manager/Associate Director Regulatory Affairs